What is claimed is:

1) A capsule dosage form comprising:

a pharmaceutical composition comprising at least 30 mg of isotretinoin or a pharmaceutically acceptable salt or ester thereof; and

a pharmaceutically-acceptable excipient;

wherein the size of the capsule is 1 to 4.

2) The capsule dosage form of claim 1, wherein said pharmaceutical composition comprises a liquid composition.

3) The capsule dosage form of claim 1, wherein said pharmaceutical composition comprises a semi-solid composition.

4) The capsule dosage form of claim 2, wherein said capsule is size 2 or smaller.

5) The capsule dosage form of claim 2, wherein said capsule is size 3 or smaller.

6) The capsule dosage form of claim 2, wherein said capsule is size 4.

7) The capsule dosage form of claim 5, wherein said pharmaceutical composition comprises at least 45 mg isotretinoin or a pharmaceutically acceptable salt or ester thereof.

8) The capsule dosage form of claim 4, wherein the ratio of isotretinoin or a pharmaceutically acceptable salt or ester thereof to isotretinoin or a pharmaceutically acceptable salt or ester thereof and pharmaceutically acceptable excipients is at least 0.20 : 1.

9) The capsule dosage form of claim 1, wherein the pharmaceutically acceptable excipient is selected from one or more oil or lipid vehicle, one or more surfactant, one or more co-surfactant and one or more antioxidant and combinations thereof.

10) The capsule dosage form of claim 1, wherein pharmaceutically acceptable excipient is selected from one or more oil or lipid vehicle, one or more surfactant, one or more co-surfactant and one or more antioxidant and combinations thereof.

11) The capsule dosage form of claim 1, wherein pharmaceutical the composition contains 30 to 60 mg of isotretinoin, 5-70% by weight of an oily vehicle, 20-80% by weight of surfactant, 1-10% by weight of co-surfactant and 0.1-5% by weight of antioxidant.

12) The capsule dosage form of claim 1, wherein the pharmaceutical composition contains 30 to 60 mg of isotretinoin, 5-70% by weight of peppermint oil, 20-80% by weight of polyoxyl 35 castor oil, 1-10% by weight of propylene glycol monocaprylate and 0.1-5% by weight of butylated hydroxyl anisole and butylated hydroxyl toluene.

13) A method for the preparation of a high dose oral pharmaceutical composition comprising isotretinoin or a pharmaceutically acceptable salt or ester thereof and at least one pharmaceutical excipient, wherein the process comprises the steps of:

(i) heating a mixture of oil, surfactant and co-surfactant at 40°C-45°C;

(ii) dissolving antioxidants to the mixture of step (i) at 40°C-45°C and then cooling to room temperature;

(iii) dispersing isotretinoin to step (ii) under stirring;

(iv) optionally, the step (iii) is followed by addition of co-solvent

(v) optionally, the step (iii) is followed by milling;

(vi) filling the mixture of step (iii) or step (iv) or step (v) in hard gelatin capsule;

(vii) preparing a gelatin banding solution by soaking gelatin in water for 6 hours at room temperature, followed by addition of polysorbate 80 at temperature of 60±10°C; and

(vii) banding the filled capsule of step (vi) with banding solution of step (vii).

14) Use of the capsule dosage form of claim 1 in the manufacture of a medicament for treating a skin disorder in a patient.

15) The use of claim 14, wherein said skin disorder comprises one of acne, lupus erythematous, and icthyosis.

16) The use of claim 15, wherein said skin disorder comprises acne.

17) The use of claim 16 wherein said acne comprises severe recalcitrant node acne.

18) The use of claim 17 wherein said patient is at least 12 years old.